ALAMEDA, Calif., March 14, 2019 /PRNewswire/ — Magnetic Insight, Inc., the leader in magnetic particle imaging (MPI) solutions, introduces the first localized MPI hyperthermia technology, HYPER, offering millimeter-scale spatial control of magnetic heating for applications in hyperthermia, drug release, and cell activation.
ALAMEDA, Calif., Dec. 12, 2018 /PRNewswire/ — Magnetic Insight, Inc., a developer and manufacturer of transformational in vivo imaging platforms, announced a Series A financing led by 5AM Ventures. The proceeds will allow the company to expand the commercial and operations teams, scale manufacturing, and develop new application areas for the technology. In conjunction with the financing, David Allison, PhD, Partner at 5AM Ventures, and Joe Victor, CEO of RareCyte Inc, will join the board of directors.
Rats and mice get a lot of bad press, but for Steve Conolly, a professor of bioengineering and of electrical engineering and computer sciences, the furry creatures have been stalwart pioneers in the development of a spectacular new medical research technology called magnetic particle imaging (MPI).
Conolly, working with colleagues, postdocs, and students in his lab, has devised groundbreaking imaging systems that use strong magnetic fields to light up targeted diseases anywhere in the body. MPI is extremely sensitive and quickly generates bright, high-contrast images, in many ways outperforming established methods such as computed tomography (CT), nuclear imaging and magnetic resonance imaging (MRI).
KANSAS CITY, Mo., April 19, 2017 /PRNewswire-USNewswire/ — The Angel Capital Association (ACA), the world’s leading professional association for accredited investors, today named three companies as finalists for the 2017 Luis Villalobos Award for ingenuity, creativity, and innovation among startups. The companies, DesignMedix Inc., Magnetic Insight, and Peloton Technology, were selected based on, among other criteria, competitive differentiation in their respective markets and demonstrated progress toward implementing the product, service, or solution. They were among many companies nominated by ACA’s membership of 13,000 angel investors.
Company initiates commercial execution of groundbreaking technology accelerating cell therapy and vascular research with magnetic particle imaging.
ALAMEDA, California, USA July 18, 2016– Magnetic Insight Inc announced today that the company has secured an oversubscribed seed round of $3M. The equity round is led by Sand Hill Angels with contributions from other prominent angel investors and funds including the Stanford-StartX Fund.
Magnetic Insight was founded to commercialize Magnetic Particle Imaging (MPI), a new imaging modality that directly detects magnetic nanoparticle tracers enabling deep tissue imaging of functional events and disease states. Because the tracer is not normally found in the body, MPI offers exceptional contrast and high sensitivity. Many traditional imaging studies involve the use of radiation or toxic agents. MPI raises the bar in imaging safety and advancement with its non-radioactive and quantitative nanoparticle detection technology. The technology is transforming preclinical research and therapy development with the promise of direct translation to the clinical.
ALAMEDA, CA May 25, 2016 – Magnetic Insight Inc, a developer of innovative imaging technologies for quantitative angiography and non-invasive cell tracking in research and the clinic, announced today that they have entered into a strategic supply agreement with Meito Sangyo, global provider of chemicals and enzymes in research, diagnostics, food processing and cosmetics. In the agreement, Magnetic Insight will develop and market VivoTrax™, a superparamagnetic iron oxide nanoparticle coated with carboxydextran, as a tracer to support stem cell and immune cell tracking in research for both magnetic particle imaging (MPI) and magnetic resonance imaging applications. The VivoTrax cell tracking kit utilizes Meito Sangyo’s Ferucarbotran product, a well-established precursor iron oxide material with translational uses in the clinic.
NEWARK, California, USA March 10, 2016 – Magnetic Insight Inc, a developer of innovative diagnostic imaging technologies, announced today a collaboration with the Stanford School of Medicine around magnetic particle imaging for solving challenges in cell therapy and vascular imaging with magnetic particle imaging. Christopher Contag, PhD, professor of pediatrics, radiology, bioengineering and of microbiology & immunology, will lead an effort to better understand early disease states in cancer and new therapeutic paths. Max Wintermark MD, professor of radiology and chief of neuroradiology at Stanford Health Care will also utilize the new imaging technology to perform quantitative cerebral perfusion and vascular studies in a variety of disease states, including stroke, traumatic brain injury, brain cancer, with the goal to eventually improve diagnosis and care in patients affected with these conditions.
Medical imaging startup raises the bar in imaging safety and sensitivity by harnessing a unique nanoparticle detection technology, transforming preclinical research and development with direct translation to clinical imaging diagnostics.
NEWARK, California, USA April 15, 2015 – Magnetic Insight Inc., a developer of innovative imaging technologies for quantitative angiography and non-invasive cell tracking in research and the clinic, announced today that the company has secured an undisclosed amount in seed funding from a prominent life science investor, and an SBIR technology award.
February 28, 2015 – Magnetic Insight has been selected to join the StartX group, a leading entrepreneurial program with an incredible legacy of developing start-ups in becoming high impact and valued companies.
February 23, 2015 – Magnetic Insight will be joining the Spring 2015 BayBio FAST Advisory program. BayBio FAST program selects the most promising young Bay Area life science companies and helps fast-track their way to funding and success by drawing on the vast and rich experience of Northern California’s vibrant life science community.